MAG200
/ Magellan Biologicals
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 07, 2025
NEXCELL-OAK: A Study to Investigate the Effectiveness, Safety, and Tolerability of MAG200 Solution for Intra-articular Injection Compared With Placebo in Participants Aged 35 to 75 Years of Age With Symptomatic Osteoarthritis of the Knee.
(clinicaltrials.gov)
- P3 | N=573 | Not yet recruiting | Sponsor: Magellan Stem Cells
New P3 trial • Immunology • Osteoarthritis • Pain • Rheumatology
September 01, 2024
Organo magadiites for diclofenac adsorption: influence of the surfactant chain.
(PubMed, Environ Sci Pollut Res Int)
- "Diclofenac removal by samples was not affected by the presence of ibuprofen, which was also removed from binary system by organophilic magadiites reaching removal of 76.5% and 86.9% by C16pyMag100% and C16pyMag200%, respectively. Regeneration studies demonstrated a drug removal percentage of 83-92% for C16pyMag and C16Mag after three cycles of adsorption."
Journal
August 20, 2024
Safety and efficacy of an allogeneic adipose-derived mesenchymal stem cell preparation in the treatment of knee osteoarthritis: A Phase I/IIa randomised controlled trial.
(PubMed, Osteoarthr Cartil Open)
- "This early-phase study provides supportive safety and efficacy evidence to progress MAG200 to later-stage trial development. ACTRN12617001095358/ACTRN12621000622808."
Journal • P1/2 data • Immunology • Osteoarthritis • Pain • Rheumatology
1 to 3
Of
3
Go to page
1